COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis

[1]  B. Fierro,et al.  Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort , 2022, Neurology international.

[2]  P. Nóbrega,et al.  Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review , 2022, Neurological Sciences.

[3]  F. Deymeer,et al.  Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID‐19 , 2022, Muscle & nerve.

[4]  Huan Yang,et al.  To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis , 2021, Frontiers in Immunology.

[5]  M. Kostic,et al.  Long-term outcome in patients with myasthenia gravis: one decade longitudinal study , 2021, Journal of Neurology.

[6]  Łukasz Rzepiński,et al.  COVID-19 pandemic year in a sample of Polish myasthenia gravis patients: an observational study. , 2021, Neurologia i neurochirurgia polska.

[7]  J. Bednařík,et al.  Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival , 2021, European journal of neurology.

[8]  P. Bini,et al.  COVID‐19 in patients with myasthenia gravis: Epidemiology and disease course , 2021, Muscle & nerve.

[9]  R. Hirschtick,et al.  Population-Based Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics , 2021, Clinical Infectious Diseases.

[10]  S. Basic,et al.  Case series of COVID-19 in patients with myasthenia gravis: a single institution experience , 2021, Acta Neurologica Belgica.

[11]  R. Rousseff.  Diagnosis of Myasthenia Gravis , 2021, Journal of clinical medicine.

[12]  D. Annane,et al.  Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis , 2021, Neurology.

[13]  E. Zanoteli,et al.  Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes , 2020, Frontiers in Neurology.

[14]  J. Finsterer,et al.  SARS‐CoV‐2 and myasthenia , 2020, Journal of medical virology.

[15]  Mike Clarke,et al.  A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.

[16]  M. Jaguszewski,et al.  COVID-19 - toward a comprehensive understanding of the disease. , 2020, Cardiology journal.

[17]  P. Adab,et al.  Covid-19: risk factors for severe disease and death , 2020, BMJ.

[18]  Gheyath K Nasrallah,et al.  Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms , 2019, Viruses.

[19]  M. Pasnoor,et al.  Diagnosis of Myasthenia Gravis. , 2018, Neurologic clinics.

[20]  M. Stankovic,et al.  Quality of life in patients with MuSK positive myasthenia gravis , 2018, Acta Neurologica Belgica.

[21]  N. Gilhus,et al.  Myasthenia gravis and infectious disease , 2018, Journal of Neurology.

[22]  M. Kurukumbi,et al.  Myasthenia Gravis: A Review , 2012, Autoimmune diseases.

[23]  T. Pekmezović,et al.  Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia) , 2012, Neurological Sciences.

[24]  M. Conaway,et al.  MG‐ADL: Still a relevant outcome measure , 2011, Muscle & nerve.

[25]  M. Pagala,et al.  Lifetime course of myasthenia gravis , 2008, Muscle & nerve.

[26]  Monica Milani,et al.  Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.